NanoBio, Merk collaborate in RSV research

Friday, December 9, 2011

NanoBio has formed a preclinical collaboration with a subsidiary of Merck, focused on the development of a vaccine for Respiratory Syncytial Virus (RSV). The studies will evaluate the combination of Merck’s proprietary RSV antigen with NanoBio’s NanoStat adjuvant technology for use as an intranasal vaccine. As part of the agreement, Merck has the option to negotiate a non-exclusive license to the NanoStat adjuvant for development of a commercial RSV vaccine.

[Read More]